High Dose Vitamin C in the Critically Ill Patient (VitC)

This study has been terminated.

(PI's add. responsibilities and time commitment prevent him from completing trial)

Sponsor:

Information provided by (Responsible Party):

Rutgers, The State University of New Jersey

ClinicalTrials.gov Identifier:

NCT01587963

First received: April 26, 2012

Last updated: March 31, 2017

Last verified: March 2017

History of Changes

Purpose

The purpose of this study is to determine the effectiveness of high doses of Vitamin C in critically ill patients.

Condition	Intervention	Phase
Shock	Drug: Ascorbic Acid Other: Ringers Lactate or Normal Saline	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	The Efficacy of High Dose Vitamin C in the Critically Ill Patient Population

Resource links provided by NLM:

MedlinePlus related topics: Shock Vitamin C

Drug Information available for: Ascorbic acid Sodium ascorbate Ringer's lactate Magnesium ascorbate

U.S. FDA Resources

Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:

Efficacy of High Dose Vitamin C Therapy in Shock Patients [ Time Frame: 30 days ]
Given the grim prognosis of septic and hypovolemic shock, we aim to study the efficacy on an alternative treatment modality by implementing high dose vitamin C therapy in our patient population. Through previous investigations, especially research in the burn patient population, we expect that high dose vitamin C therapy will be beneficial to patients with hypovolemic or septic shock.


Enrollment:	11
Study Start Date:	February 2013
Study Completion Date:	April 2015
Primary Completion Date:	February 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Ascorbic Acid Ascorbic Acid	Drug: Ascorbic Acid 66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams Other Name: Vit C
Placebo Comparator: Ringers Lactate or Normal Saline Ringers Lactate or Normal Saline	Other: Ringers Lactate or Normal Saline Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour. Other Name: Placebo

Detailed Description:

It has been shown that the stress that occurs during trauma, infection and/or shock depletes many of the body's resources such as Vitamin C (ascorbic acid) which may contribute to further complications. The purpose of this study is to determine the effectiveness of high doses of Vitamin C in critically ill patients.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Activation of the Mass Transfusion Protocol following surgery or trauma.
Diagnosis of septic shock. Septic shock will be defined as sepsis induced hypotension (i.e. systolic blood pressure <90mmHg or drop of systolic blood pressure >40mmHg in the presence of infection) that does not respond to a 2 liter fluid bolus.

Exclusion Criteria:

Age less than 18 years.
Pregnant women.
Creatinine of greater than 2.2 g/dl at time of enrollment, history of chronic kidney or end stage renal disease, rise in creatinine > 1 g/dl within 24 hours prior to enrollment.
Brain death diagnosed within 4 hours of presentation to the trauma bay or intensive care unit
Patients with history of hemolytic blood disease, e.g. glucose-6-phosphate dehydrogenase deficiency, Sickle Cell Disease and Thalassemia.
Patients in isolated cardiogenic shock.
History of liver cirrhosis
Transplant patients (liver, kidney, heart)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01587963

Locations


United States, New Jersey
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08901

Sponsors and Collaborators

Rutgers, The State University of New Jersey

Investigators


Principal Investigator:	Vicente Gracias, MD	RWJMS

More Information


Responsible Party:	Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:	NCT01587963 History of Changes
Other Study ID Numbers:	0220100048
Study First Received:	April 26, 2012
Results First Received:	October 7, 2016
Last Updated:	March 31, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Keywords provided by Rutgers, The State University of New Jersey:


hypovolemic or septic

Additional relevant MeSH terms:


Critical Illness Disease Attributes Pathologic Processes Vitamins Ascorbic Acid Micronutrients	Growth Substances Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents

ClinicalTrials.gov processed this record on September 21, 2017

To Top